|
Derivation
|
The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL). BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman.
|
|
Clinical Data
|
85 years Caucasian male The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL).
|
|
Markers
|
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
|
|
Genes Expressed
|
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
|
|
Comments
|
The BC-3 cell line contains the viral genome for Kaposi's sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8). KSHV is a recently identified and partially uncharacterized virus. BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV). They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV). The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV. BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate. The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains) or T-cell lineage-restricted antigens. The cells do express activation antigens.
|